Pharming announces topline study results on prophylactic use of Ruconest in Hereditary Angioedema

30-Nov-2010 - Pharming Group NV announced the results of its exploratory Phase II study on the safety and prophylactic effect of recombinant human C1 inhibitor ("rhC1INH") in patients with Hereditary Angioedema (HAE). The study is an open-label exploratory phase II study of the safety and prophylactic effect ...

New Long-Term Observational Study Shows Durable Viral Suppression of Boosted REYATAZ-Based Regimens

10-Nov-2010 - Results from a European Observational Study, which included 1,294 antiretroviral (ARV)-experienced patients presented at the Tenth International Congress on Drug Therapy in HIV Infection (HIV10), demonstrated a low rate of discontinuation and sustained virologic suppression with REYATAZ® ...

Pharming's Ruconest(TM) for HAE granted European Marketing Authorization

01-Nov-2010 - Pharming Group NV and Swedish Orphan Biovitrum announced that the European Commission has granted Pharming Marketing Authorization for its lead product Ruconest(TM) for the treatment of acute attacks of Hereditary Angioedema (HAE). Pharming will now receive a €5 million milestone payment from ...

Trifunctional antibody Removab from Fresenius Biotech awarded Galenus von Pergamon Prize for drug innovation

29-Oct-2010 - The trifunctional antibody Removab® (Catumaxomab) from Fresenius Biotech was awarded this year’s Galenus von Pergamon Prize in the “Specialist Care” category. The jury acknowledged Removab®’s new therapeutic mechanism and medical relevance for the treatment of malignant ascites. The Galenus von ...

Epigenomics AG: New Clinical Data for Septin9 Colorectal Cancer Blood Test

Independent validation of laboratory test used in PRESEPT Study shows that the test finds 86% of the cancers

29-Oct-2010 - Epigenomics AG announced that new data obtained in a clinical study with the Company's proprietary Septin9 biomarker for the blood-based detection of colorectal cancer were presented at the 18th United European Gastroenterology Week (UEGW) in Barcelona, Spain. The new data were presented by Dr. ...

AiCuris Announces AIC246 to be Successful in Treatment of Multiorgan HCMV Disease

22-Oct-2010 - AiCuris announced that its novel HCMV inhibitor AIC246 has been used successfully to treat a patient with multi-organ HCMV disease caused by multi-resistant virus. Details will be presented at the 48th IDSA meeting on October 23. “This is the first case, where HCMV disease has been treated and ...

EU regulators okay Qlaira for the treatment of heavy menstrual bleeding

14-Oct-2010 - Bayer Schering Pharma AG, Germany, has successfully concluded the European registration procedure for the introduction of Qlaira in the new indication treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception. The Netherlands served as Reference Member ...

Movetis receives authorisation to market Resolor in Switzerland

Switzerland is the 31st country where Resolor is authorised on the market

06-Aug-2010 - Movetis NV announced that it has received a letter from Swissmedic with the authorisation to market its lead product, Resolor (prucalopride), in Switzerland. Swissmedic granted marketing authorisation of Resolor 1mg and 2mg tablets on doctor’s prescription with the following statement: “Resolor ...

Bayer: YAZ approved in Japan for the treatment of dysmenorrhea

28-Jul-2010 - Bayer Schering Pharma AG, Germany, and Bayer Yakuhin, Ltd., Japan, announced that the Japanese regulatory authorities have granted approval for YAZ® (3 mg drospirenone/20 mcg ethinyl estradiol) for the treatment of dysmenorrhea. YAZ is available in the US, Europe, Latin America and the region ...

Pharming receives positive opinion from European Medicines Agency on Rhucin

Product name in Europe changed to Ruconest

28-Jun-2010 - Pharming Group NV announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Ruconest (Rhucin) for the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE). With this positive opinion, the ...